FDA approves third drug in Becton, Dickinson's push to supply prefilled injectables
Simplist line of generic injectables now includes ondansetron, an antiemetic currently in short supply
BD Rx Inc., a wholly owned subsidiary of Becton, Dickinson, and Co. (Franklin Lakes, NJ) has received approval for the third of its Simplist line of prefilled, generic injectables. The company, whose parent is a leading supplier of syringes, vials and other drug and device packaging, announced this effort last March, saying that it would target 20 to 30 generic injectables, typically supplied in vials, for delivery as prefilled syringes, a technology that BD is a market leader in. Ondansetron happens also to be a short-supply drug in the list that FDA maintains during the current spate of supply problems. Hospitals and clinics, the primary customers of these injectables, are contending both with limited supplies from manufacturers and with one of their leading alternative sources, compounding pharmacies, currently in upheaval because of the more rigorous enforcement of quality standards by FDA in the aftermath of the meningitis scandal of last year.
A BD spokesperson says that “a very positive response” has come from customers of the Simplist line. In promoting the use of prefilled syringes, BD notes that the 20-odd steps generally taken to obtain and administer an injectable packaged as a vial can be reduced to 12 steps with prefilled syringes. Fewer steps equals lower cost of administration, in most cases.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
